121 related articles for article (PubMed ID: 25024604)
1. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review.
Nordh S; Ansari D; Andersson R
World J Gastroenterol; 2014 Jul; 20(26):8482-90. PubMed ID: 25024604
[TBL] [Abstract][Full Text] [Related]
2. The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma.
Sahin TK; Isik A; Guven DC; Ceylan F; Babaoglu B; Akyol A; Yalcin S; Dizdar O
Pancreatology; 2024 Mar; 24(2):279-288. PubMed ID: 38272717
[TBL] [Abstract][Full Text] [Related]
3. Large-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer.
Ogunleye A; Piyawajanusorn C; Ghislat G; Ballester PJ
Health Data Sci; 2024; 4():0108. PubMed ID: 38486621
[No Abstract] [Full Text] [Related]
4. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.
Svrcek M; Cros J; Maréchal R; Bachet JB; Fléjou JF; Demetter P
Histopathology; 2015 Feb; 66(3):457-62. PubMed ID: 25298108
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Plunkett W; Huang P; Xu YZ; Heinemann V; Grunewald R; Gandhi V
Semin Oncol; 1995 Aug; 22(4 Suppl 11):3-10. PubMed ID: 7481842
[TBL] [Abstract][Full Text] [Related]
6. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Sinn M; Riess H; Sinn BV; Stieler JM; Pelzer U; Striefler JK; Oettle H; Bahra M; Denkert C; Bläker H; Lohneis P
Eur J Cancer; 2015 Aug; 51(12):1546-54. PubMed ID: 26049689
[TBL] [Abstract][Full Text] [Related]
7. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.
Li D; Pant S; Ryan DP; Laheru D; Bahary N; Dragovich T; Hosein PJ; Rolfe L; Saif MW; LaValle J; Yu KH; Lowery MA; Allen A; O'Reilly EM
Pancreatology; 2014; 14(5):398-402. PubMed ID: 25278310
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics in pancreatic cancer.
Tourkantonis IS; Peponi E; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):335-9. PubMed ID: 25076337
[TBL] [Abstract][Full Text] [Related]
9. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
11. p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines.
Moon SU; Kim JW; Sung JH; Kang MH; Kim SH; Chang H; Lee JO; Kim YJ; Lee KW; Kim JH; Bang SM; Lee JS
Cancer Res Treat; 2015 Jul; 47(3):501-8. PubMed ID: 25672581
[TBL] [Abstract][Full Text] [Related]
12. Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X; Chen W; Fan H; Zhu B
Gene; 2015 Mar; 559(1):31-7. PubMed ID: 25582275
[TBL] [Abstract][Full Text] [Related]
13. KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition.
Hamidi H; Lu M; Chau K; Anderson L; Fejzo M; Ginther C; Linnartz R; Zubel A; Slamon DJ; Finn RS
Br J Cancer; 2014 Oct; 111(9):1788-801. PubMed ID: 25167228
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer.
Ghasemi R; Rapposelli IG; Capone E; Rossi C; Lattanzio R; Piantelli M; Sala G; Iacobelli S
Oncogenesis; 2014 Aug; 3(8):e117. PubMed ID: 25133484
[TBL] [Abstract][Full Text] [Related]
15. Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer.
Donahue TR; Nguyen AH; Moughan J; Li L; Tatishchev S; Toste P; Farrell JJ
J Surg Oncol; 2014 Dec; 110(8):952-9. PubMed ID: 25132574
[TBL] [Abstract][Full Text] [Related]
16. Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.
Chen L; Zhang M; Luo S
Tumour Biol; 2014 Nov; 35(11):11551-8. PubMed ID: 25129442
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
Khawaja MR; Kleyman S; Yu Z; Howard T; Burns M; Nakeeb A; Loehrer PJ; Cardenes HR; Chiorean EG
Am J Clin Oncol; 2017 Feb; 40(1):42-46. PubMed ID: 25121637
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
Li Q; Yan H; Liu W; Zhen H; Yang Y; Cao B
PLoS One; 2014; 9(8):e104346. PubMed ID: 25093849
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.
Semrad T; Barzi A; Lenz HJ; Hutchins IM; Kim EJ; Gong IY; Tanaka M; Beckett L; Holland W; Burich RA; Snyder-Solis L; Mack P; Lara PN
Int J Clin Oncol; 2015 Jun; 20(3):518-24. PubMed ID: 25091263
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.
de Sousa Cavalcante L; Monteiro G
Eur J Pharmacol; 2014 Oct; 741():8-16. PubMed ID: 25084222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
